BPCIA Helps Amgen Gain Dismissal of Genentech Complaint

BPCIA Helps Amgen Gain Dismissal of Genentech Complaint


Recently, the U.S. District Court of Delaware dismissed a complaint filed by Genentech under the Biologics Price Competition and Innovation Act . The complaint was filed in response to Amgen seeking FDA approval to commercialize a biosimilar version of Genentech's cancer drug, Avastin.



from Biotech News